CA
NZ
UK
AU
IND
US
Connor McGogney, Chief Financial Officer of Criteo S.A. (NASDAQ:CRTO), filed a Form 4 on August 25, 2026, disclosing the automatic sale of 671 ordinary shares on August 24, 2026, to satisfy tax withholding obligations from a previously reported equity award settlement.
Director Jesse G. Singh filed a Form 4 with the SEC on August 25, 2026, disclosing multiple sales of ordinary shares and exercises of employee stock options in James Hardie Industries plc on August 21 and August 24, 2026.
Michael Kiernan, Chief Revenue Officer of Nextdoor Holdings, Inc., filed a Form 4 on August 25, 2026, disclosing the sale of Class A Common Stock on August 21, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
A Form 4 filed on August 25, 2026, reports that Douglas J. Pauls, a director of Essent Group Ltd. (NYSE:ESNT), conducted a gift transfer and an open-market sale of common shares on August 24, 2026.
Director Joseph F. Casey filed a Form 4 with the SEC on August 25, 2026, reporting the sale of 10,000 shares of Eastern Bankshares, Inc. common stock on August 24, 2026.
Lynn Seely, President and CEO of Lyell Immunopharma, Inc., filed a statement of changes in beneficial ownership on August 25, 2026, reporting an automatic sale of common stock on August 21, 2026, to cover tax obligations arising from vested restricted stock units.
A Form 4 filed on August 25, 2026, disclosed that Waters S. Davis IV, a director of Targa Resources Corp. (NYSE:TRGP), sold 2,400 shares of common stock across six tranches on August 21, 2026.
Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc., filed a statement of changes in beneficial ownership on August 25, 2026, reporting a sale of common stock on August 21, 2026, related to the settlement of vested restricted stock units.
A Form 4 filed with the SEC on August 25, 2026, discloses that J Thomas Hill, a director of Vulcan Materials CO (NYSE:VMC), sold a total of 14,000 shares of common stock on August 21, 2026, across four separate transactions.
Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc., filed a Form 4 on August 25, 2026, disclosing an automatic sale of common stock on August 21, 2026, to satisfy tax withholding obligations arising from the settlement of vested restricted stock units.
Please wait processing your request...